Aktie A40DQJ ATARA BIOTHERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Atara Biotherapeutics, Inc.

Aktien

A40DQJ

US0465132068

ATRA

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.06.2024 		% 5 Tage % 1. Jan.
8.5 USD +2.91% Intraday Chart für Atara Biotherapeutics, Inc. +3.28% -33.70%
12.06. Transcript : Atara Biotherapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM
20.05. Sektor-Update: Aktien des Gesundheitswesens geben am Montagnachmittag nach MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics : Goldman Sachs 45th Annual Global Healthcare Conference
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Sector Update: Health Care Stocks Ease Monday Afternoon
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Atara Biotherapeutics: Q1 Earnings Snapshot
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M
Atara Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc
Atara Biotherapeutics: Q4 Earnings Snapshot
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A40DQJ Aktie
  4. Nachrichten Atara Biotherapeutics, Inc.
  5. Andere Sprachen